Skip to main content
MedPathMedPath Home
Clinical Trials/SLCTR/2023/012
SLCTR/2023/012
Not Yet Recruiting
Phase 3

Impact of the SGLT2 inhibitor, empagliflozin on nephrolithiasis among non diabetes: a randomized, double-blind, placebo-controlled trial.

Professorial Medical Unit0 sitesTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsephrolithiasis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
ephrolithiasis
Sponsor
Professorial Medical Unit
Status
Not Yet Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Professorial Medical Unit

Eligibility Criteria

Inclusion Criteria

  • •Both male and female
  • •Minimum age\- 18 yrs
  • •Maximum age\- 75 yrs.
  • •Having renal parenchymal and pelvicalyceal stones
  • •With kidney stone with the size of more than four millimeters on abdominal CT scan

Exclusion Criteria

  • •\* Size less than four millimetre stones in the kidney
  • •\* Having ureteric stones
  • •\* Having known allergy to study drug
  • •\* eGFR less than 30 m2,
  • •\* Pregnant women
  • •\* Lactating women
  • •\* Kidney transplant patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Effect of SGLT2 Inhibition With Empagliflozin on Atrial Fibrillation Severity (SWEET-AF)Atrial FibrillationCardiovascular - Other cardiovascular diseases
ACTRN12621000208808The University of Adelaide300
Active, Not Recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]
EUCTR2018-001569-17-NLRadboud university medical center15
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424
NL-OMON48616Radboud Universitair Medisch Centrum15
Active, Not Recruiting
Phase 1
SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and lipid content of myocardium (EMPATROPHY)Patients with type 2 diabetes mellitus on background metformin treatment.MedDRA version: 18.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2014-003313-28-DEHannover Medical School60
Active, Not Recruiting
Phase 1
Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema
EUCTR2016-000825-38-DEHannover Medical School80